Send me real-time posts from this site at my email
finbox

Analysts Reiterate Jazz Pharmaceuticals and Astrazeneca at Buy

Here are today's top Wall Street analyst ratings where finbox.io's unbiased fair value estimates support the recommendation.

Top Upgrades and Buy Ratings

  • Mizuho raised its price target on Jazz Pharmaceuticals (Nasdaq:JAZZ) from $127 to $152 per share and reiterated its Buy rating. Eight valuation models imply an even higher fair value estimate of $180 per share representing 34% upside.

Continue reading today's top wall street ratings.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue